课题基金 / 基金详情

Cell and Gene Therapy for HIV Cure

Cell and Gene Therapy for HIV Cure
治愈艾滋病毒的细胞和基因疗法
批准号:
10593375
负责人:
KEITH R JEROME
金额:
$40.73万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-14 至 2022-06-30
关键词:

项目摘要

项目成果

KEITH R JEROME的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/总结 长期控制和治愈艾滋病毒的一个主要障碍是艾滋病毒在宿主中的持续存在, 含有潜伏感染、静止和生产性感染的CD 4 + T细胞。治愈艾滋病的唯一例子 已经提供了证据,证明寻找治愈方法是一个可以实现的目标。此外,治疗机制, 这种情况下(移植CCR 5阴性细胞)强调细胞和基因疗法代表, 也许是最有希望的治疗方法。在这里,我们提出了一个多调查员计划,以评估 领先的细胞和基因治疗方法来治愈艾滋病毒,并研究艾滋病毒储存在患者的生物学 和非人类灵长类动物接受这些治疗。我们已经召集了一个团队, 艾滋病毒、细胞和基因疗法、NHP模型和临床研究领域。我们建议3个高度集成的 初步研究重点,以追求我们的总体目标,和5个科学研究支持,将促进这些 项目初始研究重点1(IRF 1),抗HIV CAR T细胞,将由劳伦斯博士领导 Corey,Fred Hutch疫苗和传染病部门成员,联合创始人兼高级 我们的私营部门合作伙伴Juno Therapeutics的科学顾问;中心主任大卫罗林斯博士 西雅图儿童研究所的免疫和免疫疗法;和Thor瓦格纳博士,助理 西雅图儿童研究所教授。IRF 2,基于eCD 4-IG的HIV治愈疗法,将由 博士Michael Farzan,教授兼副主席,免疫学和微生物科学系,斯克里普斯 佛罗里达研究所。IRF 3,治疗性疫苗接种后T细胞的遗传保护, 由微生物学教授James Mullins博士和副教授Deborah Fuller博士指导。 微生物学,在华盛顿大学。我们假设这些细胞和基因疗法提供了 理想的,也许是最有前途的工具,以满足双重目标:1)消除潜伏感染, 病毒再激活后的细胞,以及2)提高宿主控制不可预测的再激活事件的能力, 一种治疗性减少的储库。
英文摘要
PROJECT ABSTRACT/SUMMARY A major obstacle to long-term control and cure of HIV has been the persistence of HIV in reservoirs that contain latently infected, resting, and productively infected CD4+ T cells. The single example of cure of HIV has provided evidence that the search for a cure is an achievable goal. Furthermore, the mechanism of cure in this case (transplantation with CCR5-negative cells) emphasizes that cell and gene therapies represent perhaps the most promising approach to cure. Here we propose a multi-investigator program to evaluate the leading cell and gene therapy approaches to HIV cure, and to study the biology of the HIV reservoir in patients and nonhuman primates undergoing these therapies. We have assembled a team consisting of leaders in the fields of HIV, cell and gene therapies, NHP models, and clinical research. We propose 3 highly integrated Initial Research Foci in pursuit of our overall goal, and 5 Scientific Research Supports that will facilitate these projects. Initial Research Focus 1 (IRF1), HIV-Resistant Anti-HIV CAR T Cells, will be led by Dr. Lawrence Corey, Member in the Vaccine and Infectious Disease Division at Fred Hutch, and co-founder and Senior Science Advisor of our private sector partner, Juno Therapeutics; Dr. David Rawlings, Director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute; and Dr. Thor Wagner, Associate Professor at Seattle Children's Research Institute. IRF2, eCD4-Ig based therapy for HIV cure, will be led by Dr. Michael Farzan, Professor and Vice Chair, Department of Immunology and Microbial Science, The Scripps Research Institute Florida. IRF3, Genetic protection of T cells after therapeutic vaccination, will be directed by Dr. James Mullins, Professor of Microbiology, and Dr. Deborah Fuller, Associate Professor of Microbiology, at the University of Washington. We hypothesize that these cell and gene therapies offer the ideal and perhaps most promising tools with which to meet the dual goals of 1) eliminating latently-infected cells after viral reactivation, and 2) improving the host's ability to control unpredictable reactivation events from a therapeutically-reduced reservoir.
期刊论文(22)
专著(0)
科研奖励(0)
会议论文
Autologous Stem Cell Transplantation Disrupts Adaptive Immune Responses during Rebound Simian/Human Immunodeficiency Virus Viremia.
自体干细胞移植会破坏猿猴/人类免疫缺陷病毒病毒血症反弹期间的适应性免疫反应。
DOI: 10.1128/jvi.00095-17
发表时间: 2017
期刊: Journal of virology
影响因子: 5.4
作者: [Reeves,DanielB, Peterson,ChristopherW, Kiem,Hans-Peter, Schiffer,JoshuaT]
通讯作者: Schiffer,JoshuaT
DOI: 10.1016/j.omtm.2021.06.008
发表时间: 2021-09-10
期刊: Molecular therapy. Methods & clinical development
影响因子: --
作者: [Haeseleer F, Fukazawa Y, Park H, Varco-Merth B, Rust BJ, Smedley JV, Eichholz K, Peterson CW, Mason R, Kiem HP, Roederer M, Picker LJ, Okoye AA, Corey L]
通讯作者: Corey L
Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US
参与艾滋病毒治疗研究并承担风险的意愿:对美国 400 名艾滋病毒感染者的调查结果
DOI: 10.1016/s2055-6640(20)30295-8
发表时间: 2017
期刊: Journal of Virus Eradication
影响因子: 5.5
作者: [K. Dubé, D. Evans, L. Sylla, Jeff Taylor, B. Weiner, A. Skinner, H. Thirumurthy, J. Tucker, S. Rennie, S. Greene]
通讯作者: S. Greene
DOI: 10.1097/coh.0000000000000367
发表时间: 2017-05
期刊: Current opinion in HIV and AIDS
影响因子: 4.1
作者: [Gardner MR, Farzan M]
通讯作者: Farzan M
17
    Endonuclease-mediated disruption of latent HSV as curative therapy
    Endonuclease-mediated disruption of latent HSV as curative therapy
    Endonuclease-mediated disruption of latent HSV as curative therapy
    Endonuclease-mediated disruption of latent HSV as curative therapy
    • 批准号:
      10405036
    • 项目类别:
    • 资助金额:
      $43.77万
    • 财政年份:
      2018
    • 负责人:
      KEITH R JEROME
    • 依托单位:
    国内基金
    海外基金
    综合医疗机构引入Gene-Xpert MTB/RIF技术早期发现传染性肺结核和耐药肺结核的研究
    Brahma related gene 1/Lamin B1通路在糖尿病肾脏疾病肾小管上皮细胞衰老中的作用
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2021
    • 负责人:
      龙海波
    • 依托单位:
    降钙素基因相关肽(Calcitonin gene-related peptide, CGRP)对穴位敏化的调节及机制研究
    • 批准号:
      81873385
    • 项目类别:
      面上项目
    • 资助金额:
      59.0万元
    • 批准年份:
      2018
    • 负责人:
      乔海法
    • 依托单位:
    大白菜花粉发育相关的三个孤基因(Orphan gene)的表达分析与功能鉴定
    • 批准号:
      31601771
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2016
    • 负责人:
      董相书
    • 依托单位: